Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know

Axel Heidenreich; David Pfister; Axel Merseburger; Georg Bartsch

doi:10.1016/j.eururo.2013.05.021

Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know

Axel Heidenreich^*, David Pfister, Axel Merseburger, Georg Bartsch

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Urologie

43 Zitate (Scopus)

Originalsprache	Englisch
Zeitschrift	European Urology
Jahrgang	64
Ausgabenummer	2
Seiten (von - bis)	260-265
Seitenumfang	6
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2013.05.021
Publikationsstatus	Veröffentlicht - 08.2013

Fördermittel

Axel Heidenreich has received honoraria from Astellas, Amgen, Dendreon, Ferring, IPSEN, Jansen Cilag, Sanofi Aventis, and Takeda, and he has received research grants from Astellas and Sanofi Aventis. David Pfister has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Axel Merseburger has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Georg Bartsch has nothing to disclose.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Profilbereich: Lübeck Integrated Oncology Network (LION)

Dokumente

10.1016/j.eururo.2013.05.021

Weitere Links

Link to publication in Scopus

Zitieren

@article{486f68ba3c2742d7be52892d1d8b13bd,

title = "Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know",

author = "Axel Heidenreich and David Pfister and Axel Merseburger and Georg Bartsch",

note = "Funding Information: Axel Heidenreich has received honoraria from Astellas, Amgen, Dendreon, Ferring, IPSEN, Jansen Cilag, Sanofi Aventis, and Takeda, and he has received research grants from Astellas and Sanofi Aventis. David Pfister has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Axel Merseburger has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Georg Bartsch has nothing to disclose. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2013",

month = aug,

doi = "10.1016/j.eururo.2013.05.021",

language = "English",

volume = "64",

pages = "260--265",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know

AU - Heidenreich, Axel

AU - Pfister, David

AU - Merseburger, Axel

AU - Bartsch, Georg

N1 - Funding Information: Axel Heidenreich has received honoraria from Astellas, Amgen, Dendreon, Ferring, IPSEN, Jansen Cilag, Sanofi Aventis, and Takeda, and he has received research grants from Astellas and Sanofi Aventis. David Pfister has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Axel Merseburger has received honoraria from Astellas, IPSEN, Jansen Cilag, and Sanofi Aventis. Georg Bartsch has nothing to disclose. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2013/8

Y1 - 2013/8

UR - https://www.scopus.com/pages/publications/84879969831

U2 - 10.1016/j.eururo.2013.05.021

DO - 10.1016/j.eururo.2013.05.021

M3 - Editorial

C2 - 23706522

AN - SCOPUS:84879969831

SN - 0302-2838

VL - 64

SP - 260

EP - 265

JO - European Urology

JF - European Urology

IS - 2

ER -